We started talking about these drugs the way you’d whisper about a clever shortcut into a smaller dress size. We’re ending up talking about them as a way to stay alive longer. That’s quite a journey for a weekly injection — and it’s the part of the story I actually can’t stop thinking about.
I should say where I’m standing, because it shapes how I read this. I’m at the stage of life where I’ve stopped caring much about looking younger and started caring a great deal about staying well — strong enough to lift, sharp enough to think, around long enough to be a nuisance to my children for decades yet. So a drug that wandered in through the vanity door and turned out to matter for cancer, hearts and ageing itself? That gets my full attention, and probably yours too.
The vanity drug that grew up
GLP-1 receptor agonists — the class behind semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — were already the most gossiped-about medicines on earth going into 2025. What changed by year-end wasn’t the fame. It was the subject. A run of research quietly shoved the conversation off the scales and onto something far bigger: metabolism, inflammation, and how we age.
What the studies actually found
The headlines were striking, and they deserve to be read carefully rather than swallowed whole. A UC San Diego study of more than 6,800 colon cancer patients, published in November, found that those on GLP-1 drugs were less than half as likely to die within five years as those who weren’t — 15.5% against 37.1%. That’s a big gap. But it’s an observational study: it spots an association, not a cause. The researchers themselves suspect anti-inflammatory and metabolic effects are doing the work, and they’re urgently calling for proper trials rather than victory laps. I hold findings like this the way I hold a promising rumour — interested, not convinced.
The heart data is firmer because it comes from a randomised trial. In the SUMMIT trial, tirzepatide cut the combined risk of cardiovascular death or worsening heart failure by 38% in patients with obesity-related heart failure, a stubborn condition with frustratingly few good treatments. Most of that benefit came from keeping people out of the hospital rather than from lowering deaths on its own, which is worth knowing, but keeping people out of the hospital is no small mercy.
And then the one that made the futurists sit up: the first randomised, placebo-controlled signal that semaglutide slows biological ageing — the little chemical marks on our DNA that tick along like a clock — published in Nature Communications. Genuinely intriguing. Also genuinely early: it was a small, exploratory look at a specific group (adults living with HIV), and it nudged the markers of ageing, not proven extra years of life. A slowed clock is a clue, not a promise.
Healthspan, not just lifespan
Here’s the idea that ties all of this together, and it’s the one worth taking away. Longevity researchers draw a line between lifespan — how long you live — and healthspan — how long you live well. The exciting bet buried in this research isn’t that a drug adds years to the end; it’s the geroscience hunch that if you target the underlying machinery of ageing — inflammation, dodgy metabolism — you might hold off several age-related diseases at once, rather than playing whack-a-mole with them one by one. That’s why a single class of drug turning up in cancer, heart and ageing studies at the same time is such a big deal. It hints that these things were never really separate problems.
The catch is not printed on the poster
Now the sobering half, because I’d be a poor friend to skip it. These are serious prescription medicines, not supplements. They come with real side effects — nausea, vomiting, diarrhoea are common — and a boxed warning about a rare thyroid tumour risk. They’re expensive: list prices can still top $1,000 a month without insurance, and around half of users say they’re hard to afford. The science on the exciting stuff is early, mostly about association, and often drawn from specific groups rather than people like you or me. None of this is a reason to dismiss the drugs. It’s a reason to treat them as a genuine medical decision — one for you and an actual doctor, not a headline and a hunch.
The access story is moving fast, mind you. In December, the FDA approved the first oral semaglutide pill for weight management, starting at around $149 a month without insurance, dropping the needle that had kept people away. By late 2025, roughly one in eight American adults will be taking some form of GLP-1. Whatever else is true, this is no longer a niche.
How I read it
I read all this with two feelings at once, which is usually the honest place to be. Genuine excitement that medicine might be shifting from patching up single diseases to treating ageing itself — and genuine caution, because “promising early signal” and “proven” are separated by years of hard work and more than a few dashed hopes. I’m not taking these drugs, and I’m not telling you to or not to; that’s between you and your doctor. What I am doing is watching this space closely, because the entire point of chasing more healthy years is having more of them to actually spend — on doing rather than owning, on the people and afternoons that make a long life worth wanting in the first place.
This is me thinking out loud in your company — not medical advice, and certainly not a prescription. Please take the real decisions to a real professional.
The Jacqueline Brand — knowledge builds confidence, confidence builds wealth. This is editorial commentary for inspiration, not financial or professional advice. Always do your own research. The Collection
© 2026 TheJacquelineBrand. All rights reserved. Please do not reproduce or republish without written permission.
